Boston Scientific to Acquire Devoro for ~$336M
Shots:
- Boston currently holds ~16% equity stake in Devor & acquires the remaining 84% for ~$269M up front and ~$67M upon achievement of clinical & regulatory milestones. The transaction is expected to close in Q4’21
- The acquisition will advance the peripheral interventions portfolio with the addition of Devoro’s WOLF thrombectomy platform to improve procedural efficiencies & removes blot clots
- The WOLF technology is designed to targets & capture blood using finger-like prongs that repair and remove thrombi in the arterial and venous systems without damaging blood vessels
Ref: Boston Scientific | Image: MDDI
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com